MATERNUS-Kliniken- (MAK.DE) Stock Price

Currency:

MATERNUS-Kliniken- Price

🇩🇪XETRA·CLOSED

0.92EUR

Market closed

Today +/-

-0.05 EUR

Today %

-5.29 %

MATERNUS-Kliniken- (MAK.DE) — ISIN DE0006044001. The MATERNUS-Kliniken- stock price was 0.92 EUR in 2026. MATERNUS-Kliniken- operates in the Health sector.

MATERNUS-Kliniken- stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of MATERNUS-Kliniken- over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MATERNUS-Kliniken- stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MATERNUS-Kliniken-'s price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

MATERNUS-Kliniken- Stock Price History

Date	MATERNUS-Kliniken- Price
3/5/2026	0.92 EUR
3/4/2026	0.97 EUR
2/26/2026	0.97 EUR
2/24/2026	0.91 EUR
2/20/2026	1.00 EUR
2/19/2026	1.03 EUR
2/18/2026	0.99 EUR
2/17/2026	0.95 EUR
2/16/2026	0.95 EUR
2/13/2026	0.96 EUR
2/12/2026	0.96 EUR
2/11/2026	0.96 EUR

API Docs Get API Key

MATERNUS-Kliniken- Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Revenue

EBIT

Net Income

Details

API Docs Get API Key

MATERNUS-Kliniken- Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 12, 2026, 11:31 AM

REVENUE (M EUR)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (M EUR)

NET INCOME (M EUR)

NET INCOME GROWTH (%)

SHARES (M)

DOCUMENTS

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
36	67	96	103	105	105	99	102	103	106	109	112	111	110	113	113	122	123	124	127	124	124	114	111	106	102	114
–	86.11	43.28	7.29	1.94	–	-5.71	3.03	0.98	2.91	2.83	2.75	-0.89	-0.90	2.73	–	7.96	0.82	0.81	2.42	-2.36	–	-8.06	-2.63	-4.50	-3.77	11.76
77.78	83.58	83.33	81.55	81.90	81.90	81.82	81.37	80.58	80.19	80.73	81.25	81.98	82.73	84.96	82.30	81.15	82.93	83.06	82.68	82.26	82.26	85.09	87.39	81.13	85.29	85.96
28	56	80	84	86	86	81	83	83	85	88	91	91	91	96	93	99	102	103	105	102	102	97	97	86	87	98
10	-4	0	-5	-4	-32	-6	9	-31	-4	-2	0	2	-1	-8	-12	26	2	1	-1	-1	-10	-9	-2	-14	-14	-13
–	-140.00	–	–	-20.00	700.00	-81.25	-250.00	-444.44	-87.10	-50.00	–	–	-150.00	700.00	50.00	-316.67	-92.31	-50.00	-200.00	–	900.00	-10.00	-77.78	600.00	–	-7.14
10.8	10.8	11.1	11.1	11.1	11.1	11.1	19.5	21	21	21	21	21	21	21	21	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales MATERNUS-Kliniken- generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MATERNUS-Kliniken- retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MATERNUS-Kliniken-'s gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares MATERNUS-Kliniken- has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MATERNUS-Kliniken-'s historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

ASSETS

CASH BALANCE (M EUR)

RECEIVABLES (M EUR)

OTHER RECEIVABLES (M EUR)OTHER REC. (M EUR)

INVENTORIES (k EUR)

OTHER CURRENT ASSETS (M EUR)OTHER CURRENT LIAB. (M EUR)

CURRENT ASSETS (M EUR)

TANGIBLE ASSETS (M EUR)

LONG-TERM INVESTMENTS (M EUR)LONG-T. INVEST. (M EUR)

LONG-TERM RECEIVABLES (M EUR)LONG-T. REC. (M EUR)

INTANGIBLE ASSETS (M EUR)INTANGIBLE ASSETS (M EUR)

GOODWILL (M EUR)

OTHER NON-CURRENT ASSETS (M EUR)OTHER NON-CURRENT ASSETS (M EUR)

NON-CURRENT ASSETS (M EUR)

TOTAL ASSETS (M EUR)

LIABILITIES

COMMON STOCK (M EUR)

ADDITIONAL PAID-IN CAPITAL (M EUR)

RETAINED EARNINGS (M EUR)

OTHER EQUITY (M EUR)OTHER EQUITY (M EUR)

UNREALIZED GAINS/LOSSES (M EUR)UNREAL. GAINS/LOSSES (M EUR)

EQUITY (M EUR)

LIABILITIES (M EUR)

PROVISIONS (M EUR)

OTHER SHORT-TERM LIABILITIES (M EUR)OTHER SHORT-TERM LIAB. (M EUR)

SHORT-TERM DEBTS (M EUR)SHORT-TERM DEBTS (M EUR)

SHORT-TERM PORTION OF LONG-TERM DEBTS (M EUR)LONG-TERM DEBT PORTION (M EUR)

SHORT-TERM RECEIVABLES (M EUR)SHORT-TERM REC. (M EUR)

LONG-TERM LIABILITIES (M EUR)LONG-T. LIAB. (M EUR)

DEFERRED TAXES (M EUR)

OTHER LIABILITIES (M EUR)OTHER LIAB. (M EUR)

LONG-TERM LIABILITIES (M EUR)LONG-T. LIABILITIES (M EUR)

DEBT (M EUR)

TOTAL CAPITAL (M EUR)

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

9	5.2	3.4	3.1	2.7	3.2	1.8	6.2	5.5	2.8	1.8	1.5	0.6	0.5	1.7	2.7	4.62	4.94	6.7	7.55	3.81	2.92	13.85	16.61	9.53	7.2	7.58
12.5	4	5.8	5	5.7	3.9	50.8	4	4	4.7	12.5	12.4	12.4	5	7.8	7.9	7.96	6.89	7.14	6.13	5.58	5.68	5.37	4.55	4.9	9.34	8.24
0	0	0	0	0	0	0	0.5	1.5	0.3	0.1	0.2	0.1	3	3.6	0.6	0.61	1.4	1.86	3.5	3.11	0.62	1.11	0.83	1.8	6.17	0.75
400	300	400	400	400	500	400	400	400	400	400	400	400	400	400	400	389	432	434	437	507	449	444	598	586	586	408
3.3	1.5	9.6	1.3	3.3	56.7	8.3	0.5	0.6	0.5	0.6	0.8	0.8	1.1	1.5	0.8	0.96	1.05	0.99	0.04	0.06	0.09	0.05	0.09	0.07	0.25	0.04
25.2	11	19.2	9.8	12.1	64.3	61.3	11.6	12	8.7	15.4	15.3	14.3	10	15	12.4	14.53	14.72	17.12	17.66	13.07	9.76	20.82	22.69	16.89	23.54	17.02
179.4	181.4	172.4	169.4	165.7	81.3	80.2	154.8	38.1	87.4	99.6	96.4	98.2	99	95.6	90.8	86.31	83.67	79.72	77.06	101.1	139.68	143.57	128.45	121.27	116.43	109.17
0.8	0.9	2.5	2.4	2.3	0.4	0.7	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.05	0.05	0.38	0.42	0.42	0.42	0.38	0.38	0.38	0.38	0.38
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.83	3.18	0	0
1.1	1.8	1.7	1.2	0.6	0.2	0.1	0.1	0	13.3	13.2	13.3	0.2	1.4	2	1.5	0.99	0.62	0.22	0.13	0.1	0.28	0.22	0.16	0.1	0.03	0
21.4	21.7	17.3	16.4	14.1	13.2	12.3	13.2	13.2	0	0	0	13.2	13.2	13.2	13.2	13.21	13.21	13.21	13.21	13.21	13.21	13.21	13.21	13.21	13.21	13.21
0.2	0.7	0.5	0.4	0.6	0.1	0	4.6	88.7	21	3.9	3.7	5.2	5.7	5.7	3.8	0	0.05	0.35	0	0	2.09	0.43	0.53	1.55	0.78	0.09
202.9	206.5	194.4	189.8	183.3	95.2	93.3	173.1	140.1	121.8	116.8	113.5	116.9	119.4	116.6	109.4	100.56	97.61	93.88	90.82	114.84	155.68	157.81	143.56	139.69	130.84	122.86
228.1	217.5	213.6	199.6	195.4	159.5	154.6	184.7	152.1	130.5	132.2	128.8	131.2	129.4	131.6	121.8	115.09	112.32	111	108.48	127.9	165.44	178.63	166.24	156.58	154.38	139.88

27.6	27	27.7	27.7	27.7	27.7	27.7	48.4	51.9	51.9	51.9	51.9	51.9	51.9	51.9	51.9	51.94	51.94	51.94	51.94	51.94	51.94	51.94	51.94	51.94	51.94	51.94
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3.77	3.77	3.77	3.77	3.77	3.77	3.77	3.77	3.77
26.1	21.9	16.2	11.3	6.6	-25.4	-30.2	-23.8	-54.9	-61.1	-63.9	-63	-61.3	-63.2	-77	-84.2	-57.72	-55.35	-58.05	-59.52	-61.13	-71.54	-81.11	-83.55	-95	-109.46	-122.54
0	0	0	0	0	0	0	1.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.77	5.52	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.4	0	0	0	0	0	0	0	0	0	0	0	0
53.7	48.9	43.9	39	34.3	2.3	-2.5	26	-3	-9.2	-12	-11.1	-9.4	-11.3	-19.7	-32.3	-5.78	-3.41	-2.35	-3.82	-5.43	-15.84	-25.41	-20.08	-33.78	-53.76	-66.84
2.3	50.1	52.2	48.4	7.6	9	63.6	1.6	1.8	2.1	2.8	4	4.9	3.3	5.3	5.7	6.4	7.2	6.21	6.37	4.63	4.36	4.79	4.64	4.83	5.26	3.7
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1.89	1.9	0	0	0	2.12	2.12	1.42
12.4	4.3	4.6	5.7	49	55.1	8.4	16.2	13.6	17	18.8	15.3	12	15.7	14.4	12.7	13.17	11.11	11.97	8.7	6.32	28.34	30.64	35.25	42.98	63.59	67.88
0	0	0	0	0	0	0	18.7	20.7	25.7	20.2	20	3.3	3.3	6	11.6	15.99	8.27	11.09	13.39	15.06	0	0	0	0	0	0
145.7	99	97.1	7	59.8	10.2	9.9	7.8	1.3	31.7	21.2	23.1	3.5	3.8	5	47.4	34.35	3.38	3.64	2.18	2.75	51.77	7.36	7.38	6.41	6.47	59.82
160.4	153.4	153.9	61.1	116.4	74.3	81.9	44.3	37.4	76.5	63	62.4	23.7	26.1	30.7	77.4	69.91	29.96	32.91	32.53	30.66	84.47	42.79	47.27	56.33	77.44	132.82
0	0	0	83.4	27	69.4	60.3	87.3	32.7	17.1	50.9	45.9	80.5	76.6	77.2	31.1	40.73	76.66	73.8	73.22	97.73	90.06	129.8	116.27	111.4	105.88	47.62
0	0	0	0	0	0	0	1.5	2.2	3.6	3.7	3.6	3.6	3.8	4	4	8.14	1	0	1.76	0.46	0	0	0	0.33	0.37	1.97
7.5	9.5	10.7	11.1	12.8	11.9	12.4	25.7	82.8	42.5	26.6	27.9	32.9	34.3	39.3	41.6	9.47	8.11	6.64	4.8	4.49	6.75	31.44	29.72	24.63	24.45	24.31
7.5	9.5	10.7	94.5	39.8	81.3	72.7	114.5	117.7	63.2	81.2	77.4	117	114.7	120.5	76.7	58.34	85.77	80.44	79.77	102.67	96.81	161.25	145.99	136.37	130.7	73.9
167.9	162.9	164.6	155.6	156.2	155.6	154.6	158.8	155.1	139.7	144.2	139.8	140.7	140.8	151.2	154.1	128.25	115.73	113.35	112.3	133.33	181.28	204.03	193.26	192.7	208.14	206.72
221.6	211.8	208.5	194.6	190.5	157.9	152.1	184.8	152.1	130.5	132.2	128.7	131.3	129.5	131.5	121.8	122.47	112.32	111	108.48	127.91	165.44	178.63	173.18	158.92	154.38	139.88

Details

Balance Sheet

ⓘ

What Is the Balance Sheet?

The balance sheet is a financial snapshot of MATERNUS-Kliniken- at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives MATERNUS-Kliniken- financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means MATERNUS-Kliniken- is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether MATERNUS-Kliniken- is strengthening or weakening its financial position.

API Docs Get API Key

MATERNUS-Kliniken- Stock Quarterly Figures

REVENUE (M EUR)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (M EUR)

NET INCOME (M EUR)

NET INCOME GROWTH (%)

SHARES (M)

2001 Q1	2001 Q2	2001 Q3	2001 Q4	2002 Q1	2002 Q2	2002 Q3	2002 Q4	2003 Q1	2003 Q2	2003 Q3	2003 Q4	2004 Q1	2004 Q2	2004 Q3	2004 Q4	2005 Q1	2005 Q2	2005 Q3	2005 Q4	2006 Q1	2006 Q2	2006 Q3	2006 Q4	2007 Q1	2007 Q2	2007 Q3	2007 Q4	2008 Q1	2008 Q2	2008 Q3	2008 Q4	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	2010 Q3	2010 Q4	2011 Q1	2011 Q2	2011 Q3	2011 Q4	2012 Q1	2012 Q2	2012 Q3	2012 Q4	2013 Q1	2013 Q2	2013 Q3	2013 Q4	2014 Q1	2014 Q2	2014 Q3	2014 Q4	2015 Q1	2015 Q2	2015 Q3	2015 Q4	2017 Q1	2017 Q2	2018 Q1	2018 Q2	2018 Q4	2019 Q1	2019 Q2	2019 Q4	2020 Q1	2020 Q2	2020 Q4	2021 Q2	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q4	2024 Q2	2024 Q4	2025 Q2
24	26	25	29	25	25	28	31	25	27	27	33	24	25	26	26	25	26	26	44	25	26	27	27	26	27	28	30	26	27	29	29	27	28	29	30	27	29	29	34	27	28	29	32	27	28	29	28	27	28	29	29	28	30	31	31	30	30	31	30	31	31	30	30	124	30	31	61	28	27	114	28	111	26	28	25	106	25	25	102	57	56	59
–	8.33	-3.85	16.00	-13.79	–	12.00	10.71	-19.35	8.00	–	22.22	-27.27	4.17	4.00	–	-3.85	4.00	–	69.23	-43.18	4.00	3.85	–	-3.70	3.85	3.70	7.14	-13.33	3.85	7.41	–	-6.90	3.70	3.57	3.45	-10.00	7.41	–	17.24	-20.59	3.70	3.57	10.34	-15.63	3.70	3.57	-3.45	-3.57	3.70	3.57	–	-3.45	7.14	3.33	–	-3.23	–	3.33	-3.23	3.33	–	-3.23	–	313.33	-75.81	3.33	96.77	-54.10	-3.57	322.22	-75.44	296.43	-76.58	7.69	-10.71	324.00	-76.42	–	308.00	-44.12	-1.75	5.36
83.33	80.77	84.00	79.31	80.00	88.00	82.14	77.42	84.00	81.48	85.19	81.82	83.33	84.00	80.77	80.77	84.00	80.77	80.77	88.64	80.00	80.77	85.19	81.48	80.77	81.48	82.14	80.00	80.77	81.48	79.31	82.76	81.48	82.14	82.76	83.33	81.48	82.76	82.76	85.29	81.48	82.14	82.76	84.38	81.48	85.71	86.21	75.00	81.48	82.14	82.76	75.86	82.14	80.00	83.87	80.65	83.33	83.33	80.65	83.33	83.87	83.87	83.33	83.33	82.26	83.33	80.65	83.61	82.14	85.19	85.09	85.71	87.39	84.62	78.57	8.00	81.13	84.00	92.00	85.29	87.72	85.71	88.14
20	21	21	23	20	22	23	24	21	22	23	27	20	21	21	21	21	21	21	39	20	21	23	22	21	22	23	24	21	22	23	24	22	23	24	25	22	24	24	29	22	23	24	27	22	24	25	21	22	23	24	22	23	24	26	25	25	25	25	25	26	26	25	25	102	25	25	51	23	23	97	24	97	22	22	2	86	21	23	87	50	48	52
0	0	1	-5	-1	-1	0	-2	-2	0	0	-28	-2	-2	0	-10	-1	-1	0	13	-2	-1	0	-26	-2	-1	0	-1	-2	-1	0	0	0	0	1	1	0	0	0	1	0	-1	0	0	-1	-1	0	-6	-2	-2	-1	-7	0	-1	0	28	0	0	0	3	0	0	0	0	-1	-2	-1	-6	-2	-1	-9	-1	-2	-1	-2	-5	-14	-5	-3	-14	-1	-11	-2
–	–	–	-600.00	-80.00	–	–	–	–	–	–	–	-92.86	–	–	–	-90.00	–	–	–	-115.38	-50.00	–	–	-92.31	-50.00	–	–	100.00	-50.00	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-66.67	–	-50.00	600.00	–	–	–	–	–	–	–	–	–	–	–	–	–	100.00	-50.00	500.00	-66.67	-50.00	800.00	-88.89	100.00	-50.00	100.00	150.00	180.00	-64.29	-40.00	366.67	-92.86	1,000.00	-81.82
11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	11.08	44.62	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	21.43	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	20.97	21.2	20.97	20.97	20.97	21.73	22.38	20.86	20.52	20.38	20.97	19.69	20.97	20.93	21.26	21.34	20.97	21.14	21.33	20.97	20.5	21.44	21.03

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

API Docs Get API Key

MATERNUS-Kliniken- stock margins

The MATERNUS-Kliniken- margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MATERNUS-Kliniken-. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MATERNUS-Kliniken-.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

API Docs Get API Key

MATERNUS-Kliniken- Stock Sales Revenue, EBIT, Earnings per Share

The MATERNUS-Kliniken- earnings per share therefore indicates how much revenue MATERNUS-Kliniken- has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Sales per Share

EBIT per share

Earnings per Share

Details

API Docs Get API Key

MATERNUS-Kliniken- business model

Maternus Kliniken AG is a leading company in the German healthcare industry. The company has a history dating back to 1908 when the foundation for the first clinic was laid. Since then, the company has developed into a diverse corporation with various divisions and offerings. The business model of Maternus Kliniken AG is focused on providing people with high-quality and effective medical services. The company emphasizes holistic treatment of diseases and injuries. The company philosophy of Maternus Kliniken AG is that health is a valuable asset that needs to be nurtured, protected, and preserved. The company now operates several clinics throughout the country, specializing in different medical activities. One of the most well-known divisions of Maternus Kliniken AG is the geriatric clinics, which specialize in treating older people. Here, patients are treated for conditions such as spasms, dizziness, falls, or other age-related ailments that require professional help. In addition to geriatric clinics, Maternus Kliniken AG also operates clinics for cardiology, orthopedics, and neurology. Here, diseases of the heart, bones, and nervous system are treated. Furthermore, the company has a psychiatry department. Another focus of Maternus Kliniken AG is outpatient services. Services such as physiotherapy, occupational therapy, and speech therapy are offered. The company also provides rehabilitation measures for patients who require rehabilitation following treatment or surgery. However, Maternus Kliniken AG is not only specialized in medical treatments. For several years now, the company has also offered a wide range of wellness programs. Here, patients can spend a relaxing time, recover, and recharge their energy. The wellness offering includes services such as massages, yoga classes, fitness programs, as well as weight loss programs. Overall, it can be said that Maternus Kliniken AG is a very diverse company that caters to many different needs of patients. The company philosophy, emphasis on holistic treatment, and wide range of offerings make it an important player in the German healthcare sector.

API Docs Get API Key

MATERNUS-Kliniken- SWOT Analysis

Strengths

Maternus Kliniken AG possesses several strengths that contribute to its success in the market. These strengths include:

Strong brand reputation and recognition
Wide range of specialized healthcare services
State-of-the-art medical facilities and equipment
Experienced and highly skilled medical professionals
Strong financial position and stability

Weaknesses

Despite its strengths, Maternus Kliniken AG also faces certain weaknesses that may hinder its overall performance and growth. These weaknesses include:

Reliance on a limited geographic presence, which limits market reach
Potential for high costs associated with maintaining modern medical equipment
Dependency on third-party insurance providers for revenue
Lack of diversification in service offerings
Issues with internal communication and coordination between departments

Opportunities

Maternus Kliniken AG has several opportunities to capitalize on in the market. These opportunities include:

Expansion into new geographic regions to reach a broader customer base
Growing demand for specialized healthcare services
Collaborations with other healthcare providers to offer comprehensive solutions
Investment in research and development to stay at the forefront of medical advancements
Introduction of innovative service offerings to attract more patients

Threats

Maternus Kliniken AG faces certain threats in the competitive market. These threats include:

Increase in competition from other healthcare providers
Regulatory changes impacting reimbursement rates and healthcare policies
Economic downturns affecting patients' ability to afford healthcare services
Technological advancements leading to potential disruption in traditional healthcare models
Negative publicity or reputation damage impacting patient trust and loyalty

API Docs Get API Key

MATERNUS-Kliniken- Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

API Docs Get API Key

MATERNUS-Kliniken- historical P/E ratio, EBIT multiple, and P/S ratio

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides MATERNUS-Kliniken-'s share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates MATERNUS-Kliniken-'s market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots MATERNUS-Kliniken-'s valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if MATERNUS-Kliniken- grows earnings faster than its peers.

API Docs Get API Key

MATERNUS-Kliniken- annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

API Docs Get API Key

MATERNUS-Kliniken- shares outstanding

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

API Docs Get API Key

MATERNUS-Kliniken- stock splits

In MATERNUS-Kliniken-'s history, there have been no stock splits.

API Docs Get API Key

MATERNUS-Kliniken- Dividend History

1 years of dividend payments

YearAnnual DividendYoY ChangePayments

20000.38EUR—1×

API Docs Get API Key

Unfortunately, there are currently no price targets and forecasts available for MATERNUS-Kliniken-.

API Docs Get API Key

MATERNUS-Kliniken- shareholders

%	Name	Stocks	Change	Date
81.69876%	Wohlers de Meie (Sylvia)	17,132,230		7/15/2025

API Docs Get API Key

MATERNUS-Kliniken- Executives and Management Board

Dr. Daniela Rossa-heise

Chairwoman of the Supervisory Board · since 2017

Compensation100,000EUR

Compensation100,000 EUR

Mr. Sven Olschar

Deputy Chairman of the Supervisory Board, Employee Representative · since 2008

75,000EUR

Compensation75,000 EUR

Mr. Joerg Arnold

Member of the Supervisory Board, Employee Representative

50,000EUR

Compensation50,000 EUR

Ms. Sabine Bader

Member of the Supervisory Board, Employee Representative

50,000EUR

Compensation50,000 EUR

Ms. Sylvia De Meie

Member of the Supervisory Board, Employee Representative

50,000EUR

Compensation50,000 EUR

API Docs Get API Key

MATERNUS-Kliniken- Research

Soon

Deep-dive analyses, investment theses, and proprietary research — curated by Eulerpool.

Research reports are coming soon

We're building institutional-grade equity research for MATERNUS-Kliniken- and thousands of other companies.

Most common questions regarding MATERNUS-Kliniken-

The business model of Maternus Kliniken AG is focused on providing healthcare services through its network of hospitals and clinics. The company operates in the field of acute and rehabilitative care, specializing in orthopedics, neurology, cardiology, and psychosomatic medicine. Maternus Kliniken AG aims to offer high-quality medical treatment, customized care plans, and advanced medical technologies to ensure the well-being and recovery of its patients. With a patient-centric approach, Maternus Kliniken AG strives to be a leading healthcare provider, delivering comprehensive and specialized services to improve the lives of individuals in need of medical care.

The Maternus Kliniken AG is a leading company in the healthcare industry and offers a wide range of medical services. The company operates in several sectors, including rehabilitation, elderly care, and outpatient care. Maternus' rehabilitation clinics focus on the treatment of musculoskeletal disorders, neurological disorders, cardiovascular diseases, and addiction disorders. The company operates eleven rehabilitation clinics in Germany and offers both inpatient and outpatient rehabilitation treatments. Maternus also operates elderly care facilities that provide comprehensive care and support for older people. The facilities are tailored to the needs of older individuals and offer a familial atmosphere where residents feel comfortable and safe. The care offerings range from assisted living and nursing home placements to mobile nursing services. Maternus' outpatient care offers a wide range of services tailored to the individual needs of customers. The services include basic care, medical care, household support, and caregiving. In addition to medical services, Maternus also offers various products that can be used for rehabilitation and care. These include various aids such as wheelchairs, walkers, hospital beds, and care clothing. The business model of Maternus Kliniken AG is based on the vision of promoting health and well-being for all and providing comprehensive medical care at the highest level. The company aims to continuously improve and expand its services to meet the needs of its customers. With a dedicated and competent workforce and state-of-the-art medical equipment, Maternus ensures high-quality medical care for all patients. Maternus Kliniken AG is prepared for the legal and economic changes in the healthcare sector and responds quickly and flexibly to market changes. The company places great emphasis on efficient and cost-effective processes in order to offer high-quality services at competitive prices. Overall, Maternus Kliniken AG offers a wide range of medical services and products tailored to the individual needs of customers. With a focus on quality and innovation, the company strives to meet the needs of its customers and provide comprehensive medical care at the highest level.

API Docs Get API Key

Fair ValuePRO

0.78 EUR

Over-/UndervaluationPRO

7.0% undervalued

Expected Return

18.86 %

Sector

Health

Industry

Health Care Facilities

Number of shares

20,970,000

Employees

1,726

Revenue per Employee

66,050.98 EUR

Revenue growth Ø5 years

-0.05 %

EBIT growth Ø5 years

—

Net Income growth Ø5 years

6.46 %

Website maternus.de

Country

Germany 🇩🇪

Currency

EUR

Initial public offering

Apr 2, 1997

ISIN

DE0006044001

Cusip

D31880103

Sedol

5134335

Market capitalization

19.92 M EURMicro Cap

52-Week Range

0.91–1.03EUR

MATERNUS-Kliniken- Directors Dealings

Quality Investing

Details

3 / 10

Sales growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

—

P/E ratio

-1.47

P/Ee

—

P/S

0.17

P/Se

—

EV/EBIT

—

P/B Ratio

—

ROE (Return on Equity)

19.68 %

ROA (Return on Assets)

-9.41 %

ROCE (Return on Capital Employed)

3.42 %

ROIC (Return on Invested Capital)

-6.05 %

Gross Margin

86.65 %

EBIT Margin

-2 %

Net Margin

-11.54 %

EPS (Earnings Per Share)

-0.63 EUR

Net Debt / EBIT

-45.78

Debt/Equity

-1.61

Last updated Mar 12, 2026, 11:31 AM

MATERNUS-Kliniken- Peer Group

MATERNUS-Kliniken- Ticker

DÜSSELDORF · MAK.DUFRANKFURT · MAK.FHAMBURG · MAK.HMLONDON · 0N2K.LMUNICH · MAK.MUSIX · MAK.SWXETRA · MAK.DE

MATERNUS-Kliniken- FIGI

MAK:GR · BBG000BM1H27MAK:GF · BBG000BM1H81MAK:GD · BBG000BM1HL6MAK:GY · BBG000BM1HT8MAK:GS · BBG000BM1J14MAK:GM · BBG000BM1JL2MAK:GB · BBG000BM1JW0MAK:GI · BBG000BM1KC9MAK:GH · BBG000BM1KM8MAK:EO · BBG000D8DFN4MAK:XH · BBG000D8DGN2MAK:XC · BBG000D8DHF9MAK:XF · BBG000D8DHZ7MAK:XE · BBG000D8DJK9MAK:XJ · BBG000D8DKP1MAK:XL · BBG000D8DKX2MAK:XG · BBG000D8DL79MAK:XO · BBG000D8DLF0MAK:XS · BBG000D8DMX8MAK:XA · BBG000D8DN11MAK:E1 · BBG000D8DNV8MAK:XT · BBG000D8DP25MAK:XW · BBG000D8DP98MAK:EU · BBG000D8FRL8MAK:TH · BBG00163S0W8MAKD:S1 · BBG001MBZ0N4MAK:XV · BBG00591G384MAKD:L3 · BBG006T9RGF4MAKD:B3 · BBG006TBKDG2MAK:QT · BBG0077H9MK9MAKD:PO · BBG008H04BC1MAK:XX · BBG00JN7CR77MAK:SW · BBG00LVDXYQ1MAK:BW · BBG00LVDXYX3MAK:GZ · BBG00XS4QFD2MAKD:L1 · BBG00Y9237J2MAKD:S4 · BBG00YJ84TD50N2K:LN · BBG012GNSPR1MAK:LA · BBG018H7KZZ9MAK:LU · BBG018J172F0

All fundamentals about MATERNUS-Kliniken-

Our stock analysis for MATERNUS-Kliniken- Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MATERNUS-Kliniken- Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

MATERNUS-Kliniken- Revenue→

MATERNUS-Kliniken- Net Income→

MATERNUS-Kliniken- P/E→

MATERNUS-Kliniken- P/S→

MATERNUS-Kliniken- EBIT→

MATERNUS-Kliniken- Dividend→

MATERNUS-Kliniken- Directors Dealings→

MATERNUS-Kliniken- Stocks→

MATERNUS-Kliniken- Market capitalization→

MATERNUS-Kliniken- Debt→

MATERNUS-Kliniken- Liabilities→

MATERNUS-Kliniken- Equity→

MATERNUS-Kliniken- AAQS→

MATERNUS-Kliniken- Employees→

MATERNUS-Kliniken- ROE→

MATERNUS-Kliniken- ROA→

MATERNUS-Kliniken- ROCE→

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
11	-5	0	-5	-4	-34	-6	16	-25	0	2	5	7	3	-4	-8	27	2	0	0	-2	-12	-7	-1	-12	-12	-10
11	7	6	6	7	36	5	6	33	4	5	4	0	1	5	5	5	5	4	5	5	11	11	11	11	9	12
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	-2	0	1	1	0	-2	-25	-8	-1	-13	-7	-5	0	3	3	7	-8	4	7	7	18	1	1	1	-1	1
-24	0	-1	0	0	0	1	0	0	-2	0	0	0	0	0	2	-29	-2	-1	-3	-4	-1	6	6	4	7	11
0	0	0	0	0	0	0	6	6	5	5	5	5	5	4	4	4	1	3	5	5	7	7	6	5	7	4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	-1	4	3	4	2	0	-3	0	1	-5	3	1	5	4	3	11	-2	7	9	6	16	12	17	4	2	15
-1	-11	-4	-2	-2	-1	-2	-2	-1	0	0	-1	-1	-3	-2	0	0	-2	0	0	0	0	0	-1	-2	-3	-1
-38	-9	-4	5	-1	0	0	-2	-1	-1	0	-1	-1	-3	-2	0	0	-2	0	0	0	0	0	-1	-2	-3	-1
-36	2	0	8	0	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
41	-1	0	-9	-3	-2	0	-8	-7	-5	7	-1	-1	-2	-1	-2	-1	7	-1	-3	-3	-8	4	-6	-6	7	-7
0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
39	-1	-1	-9	-3	-2	0	7	0	-5	7	-1	-1	-2	-1	-2	-6	6	-5	-8	-9	-16	-2	-12	-12	0	-11
-1	0	-2	0	0	0	0	15	4	0	0	0	0	0	0	0	-4	-1	-3	-5	-5	-7	-7	-5	-5	-7	-4
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	-12	-1	0	0	0	-1	2	-1	-4	1	0	-1	0	0	0	4	1	1	0	-3	-1	9	2	-10	-1	2
-1.57	-12.69	-0.01	1.21	2.54	1.13	-3.27	-5.59	-1.02	0.89	-5.58	1.65	-0.05	2.32	1.7	2.48	10.62	-5.16	7.09	8.53	5.29	15.07	11.43	15.32	2.33	-1.44	13.86
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

MATERNUS-Kliniken- (MAK.DE) Stock Price

MATERNUS-Kliniken- Price

MATERNUS-Kliniken- stock price

Stock Price

How to Read This Chart

Total Return vs. Price Return

Intraday Price Data

What to Look For

MATERNUS-Kliniken- Revenue, EBIT, Net Income

MATERNUS-Kliniken- Income Statement, Balance Sheet, Cash Flow Statement

Income Statement Key Figures

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

Balance Sheet

What Is the Balance Sheet?

Assets

Liabilities

Shareholders' Equity

Key Ratios to Derive

MATERNUS-Kliniken- Stock Quarterly Figures

Income Statement Key Figures

Revenue and Revenue Growth

Gross Margin

EBIT and EBIT Margin

Net Income and Earnings Per Share (EPS)

Shares Outstanding

Analyst Estimates

MATERNUS-Kliniken- stock margins

MATERNUS-Kliniken- Stock Sales Revenue, EBIT, Earnings per Share

MATERNUS-Kliniken- business model

MATERNUS-Kliniken- SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

MATERNUS-Kliniken- Eulerpool Fair Value

Fair Value Estimate

What Is Fair Value?

Earnings-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

How to Use This Chart

MATERNUS-Kliniken- historical P/E ratio, EBIT multiple, and P/S ratio

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

Price-to-Sales Ratio (P/S)

Price-to-EBIT Ratio

How to Use This Chart

MATERNUS-Kliniken- annual returns

Annual Return

What This Chart Shows

Price Return

Dividend Return

What to Look For

MATERNUS-Kliniken- shares outstanding

MATERNUS-Kliniken- shareholders

MATERNUS-Kliniken- Executives and Management Board

Dr. Daniela Rossa-heise

Mr. Sven Olschar

Mr. Joerg Arnold

Ms. Sabine Bader

Ms. Sylvia De Meie

MATERNUS-Kliniken- Research

Most common questions regarding MATERNUS-Kliniken-

What is the business model of MATERNUS-Kliniken-?

In which industries is MATERNUS-Kliniken- primarily active?

Who are the main competitors of MATERNUS-Kliniken- in the market?

What is the history and background of the company MATERNUS-Kliniken-?

What significant milestones has the company MATERNUS-Kliniken- achieved?

In which countries and regions is MATERNUS-Kliniken- primarily present?

What values and corporate philosophy does MATERNUS-Kliniken- represent?

What is the business model of MATERNUS-Kliniken-?

What is the revenue of MATERNUS-Kliniken- 2026?

How high is the profit of MATERNUS-Kliniken- 2026?

What is the P/E ratio of MATERNUS-Kliniken- 2026?

What is the P/S ratio of MATERNUS-Kliniken- 2026?